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Background: Multiple randomized controlled trials have documented the effectiveness of rivaroxaban in
the prevention of venous thromboembolism up to 1-month following total joint arthroplasty. However,
the effectiveness and safety of rivaroxaban in the real-world setting, outside of the strict protocols used
by randomized clinical trials, are unknown.
Methods: This was a prospective, observational, noninterventional, phase IV study of 3914 consecutive
patients who underwent total joint arthroplasty from June 2010 to December 2012. Patients were treated
with rivaroxaban 10 mg by mouth daily starting postoperative day 1 and continued for 15 days. Par-
ticipants were followed up in clinic at 6 weeks and contacted by telephone at 12 weeks. The primary
outcome of interest was symptomatic venous thromboembolism; secondary outcomes included bleeding
events, transfusion requirements, and death.
Results: The incidence of symptomatic deep venous thrombosis at 3 months was 0.5% (n ¼ 18). Only 1
deep venous thrombosis event occurred within 7 days of surgery. The incidence of symptomatic
pulmonary embolism (PE) at 3 months was 0.7% (n ¼ 28). Thirteen PEs (46%) occurred within 7 days of
surgery. The rate of major bleeding while on prophylaxis was 0.1%. Only 5% of patients received a blood
transfusion. No deaths were attributed to thromboembolic events.
Conclusion: This prospective, observational, phase IV study demonstrates that rivaroxaban appears to
protect patients against symptomatic PE and is not associated with major bleeding events when used in a
real-world setting as described.
© 2016 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Four randomized controlled trials have documented the effec-
tiveness of rivaroxaban compared with enoxaparin in the preven-
tion of radiographic deep venous thrombosis (DVT) or a compositeclosed potential or pertinent
ent, either direct or indirect,
the biomedical ﬁeld which
rest with this work. For full
6/j.arth.2016.09.021.
, MA, Sunnybrook Research
llesley Street East, Suite 319,
r Inc. This is an open access article uoutcome of any DVT and nonfatal pulmonary embolism (PE) with
acceptable levels of bleeding following total hip arthroplasty (THA)
[1,2] and total knee arthroplasty (TKA) [3,4]. However, the effec-
tiveness of rivaroxaban in the real-world setting, outside of the
strict protocols used by randomized clinical trials, is unknown.
Furthermore, by design, these randomized controlled trials
document radiographic and not necessarily symptomatic rates of
DVT and PE, thus not reﬂecting real-world symptomedriven
investigations and rates of venous thromboembolism (VTE).
Our purpose was to document the efﬁcacy (ie, symptomatic
thromboembolic events) and safety (ie, bleeding events as well
as deaths) following primary and revision THA and TKA in ander the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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of rivaroxaban. The shorter duration of treatment for THAwas used
because patients are mobilized weight-bearing as tolerated on
postoperative day (POD) 1 inmost cases and there is less soft-tissue
dissection with smaller incisions.
Materials and Methods
This was a phase IV, prospective, observational, noninterven-
tional study. Phase IV studies are an essential complement to
tightly controlled randomized controlled trials as they supplement
the previously published efﬁcacy data and characterize the true
safety proﬁle of medication in a naturalistic setting.
All patients underwent surgery in a high-volume, academic
arthroplasty center in Toronto, Ontario, Canada. All patients 18
years or older scheduled to undergo either primary or revision THA
and TKA between June 16, 2010, and December 14, 2012, were
screened for contraindications for the use of rivaroxaban according
to manufacturer's guidelines. All eligible patients were approached
and informed consent was obtained. The study protocol was
approved by the institutional research ethics board.
Patient Data
Demographic data were abstracted from charts prospectively
and included age, gender, body mass index (BMI), and risk factors
for thromboembolic disease (ie, history of previous VTE, current
platelet count >500,000, BMI >30, major surgery within 3 months,
cancer treatment within 3 months, and being wheelchair bound).
Anesthetic and surgical details including type of anesthetic, use of
regional blocks, procedure time from surgical start to surgical
closure, estimated blood loss (ie, total suction volume plus ﬂuid
from weighed sponges less irrigation volume), time to ﬁrst dose
anticoagulant, perioperative blood values, and date of discharge
were collected.
Thromboprophylaxis
Patients were treated with rivaroxaban 10 mg by mouth daily
starting POD 1 and continued for 15 days. Patients were not
recruited for this study if they were pregnant, breast feeding, had
active bleeding, substantial liver disease (ie, international normal-
ized ratio greater than 1.3 without anticoagulation), severe renal
impairment (ie, glomerular ﬁltration rate less than 30), concomi-
tant use of protease inhibitors for the treatment of human immu-
nodeﬁciency virus infection or were on long-term anticoagulation
(ie, for a condition that rivaroxaban was not licensed in Canada).
Only patients who had an epidural anesthetic (n ¼ 127, 3.2%)
were treated with dalteparin or enoxaparin while the epidural
catheter was in situ and started on rivaroxaban the day after the
catheter was removed, usually POD 2 or 3. No intermittent
compressive devices or thromboembolic stockings were used post-
operatively. No intraoperative unfractionated heparin was used.
Aspirin was not used routinely. Patients were mobilized POD 1
weight-bearing as tolerated for primary arthroplasties. A small
number of cases were partial weight-bearing due to osteotomy,
greater trochanter stabilization, or with elevated BMI following THA.
Surgery
Nine arthroplasty surgeons contributed cases to this study. Of
the 9 surgeons, 7 used a direct lateral approach for their primary
THA, 1 used an anterolateral approach, and 1 used a posterior
approach. All cases were done with lateral positioning. No intra-
operative or postoperative blood salvage techniques were used.Type of anesthetic, surgical time, and estimated blood loss are
reported. All 9 surgeons used anteromedial incision for TKA. One
surgeon used a lateral parapatellar approach for severe valgus
knees. All surgeons used a tourniquet. Five of 9 surgeons deﬂated
the tourniquet before closure. All surgeons used a light compressive
dressing with tensor bandages and a knee immobilizer. There was
no routine use of tranexamic acid or drains.
Follow-Up
Participants were followed up in clinic at 6 weeks where a self-
report questionnaire was completed. Patients were contacted by
telephone at 12weeks and asked the same questions as were on the
questionnaire at 6 weeks. For those who were lost to follow-up,
searches of electronic medical records at our institution and of a
web-based application that gathers patients' results and informa-
tion from various other institutions in our regionwere undertaken.
An online search for obituaries was undertaken for patients whose
questionnaires or electronic medical records were not available.
Outcomes
The primary outcome of interest was the incidence of symp-
tomatic, proximal DVT and/or symptomatic PE by the end of post-
operative week 12. Doppler ultrasound was used to diagnose
symptomatic, proximal DVT (ie, occlusion or lack of ﬂow in popli-
teal, femoral, and/or iliac veins). Spiral computed tomography
angiogram, angiogram, or ventilation-perfusion scans were used to
diagnose symptomatic PE (ie, central or segmental ﬁlling defects).
Sub-segmental ﬁlling defects were not included in the deﬁnition of
a positive PE. All Doppler ultrasound, computed tomography
angiogram, angiogram, and ventilation-perfusion scans were
reviewed by a radiologist to verify ﬁndings. All thromboembolic
events detected were managed according to local guidelines.
Incidence of symptomatic DVT and PE was calculated from
postoperative weeks 0 to 12 and was displayed graphically in
cumulative incidence plots. Incidence rates were stratiﬁed by type
of surgery.
Secondary outcomes of interest included major and nonmajor
bleeding, transfusion, and death. Bleeding events were monitored
for the full duration of follow-up. Categorization of bleeding events
was more stringent compared to the RECORD trials as the need for
interventional radiology was considered a major bleeding event.
Bleeding events categorized as not clinically relevant are not
reported. Previously deﬁned major and nonmajor bleeding events
were reviewed by a hospitalist to conﬁrm the severity of the
bleeding episode (Fig. 1). Bleeding complications were documented
as “on prophylaxis” when they occurred between 2 hours after the
ﬁrst dose of anticoagulant therapy and 24 hours after the 15th dose.
Bleeding complications were categorized as surgical site and
nonsurgical site bleeding. In the case of death, autopsy reports were
obtained where available.
Statistical Analysis
Means and standard deviations were calculated for continuous,
normally distributed variables. Medians and interquartile ranges
(IQR) were calculated for continuous variables with a non-normal
distribution. Absolute and relative frequencies were measured for
discrete variables. Baseline patient characteristics were compared
using c2 test and nonparametric methods, as appropriate. Relative
risk (RR) ratios were calculated for potential risk factors. Statistical
analysis was performed using SAS version 9.3 (SAS Institute, Cary,
NC). Statistical results are reported using 2-tailed P values with
signiﬁcance set at P < .05.
Fig. 1. Classiﬁcation of bleeding events.
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From June 16, 2010, to December 14, 2012, 4900 adult patients
underwent total joint arthroplasty and 4152 (85%) agreed to
participate in the study (Fig. 2). Two hundred and thirty-eight
patients were excluded as they received an anticoagulant other
than rivaroxaban. Therefore, data of 3914 patients were used for
analysis. Only 74 patients (1.9%) did not complete the 12-week
telephone questionnaire per protocol. Of these, 62 were shown to
have contact with the health-care system with laboratory or X-ray
reports after the 3-month follow-up indicating they were alive.
None of the remaining 12 (0.3%) patients appeared in an online
search for an obituary and were deemed to be likely alive at the
completion of the study period.
Study Population
Baseline patient and operative characteristics across procedure
types are displayed in Table 1. Patients who underwent TKA
represented 59% of the population (n ¼ 2316) while those who
underwent THA represented the remaining 41% (n ¼ 1598). The
majority of patients were women (61%, n ¼ 2381). Average age was
65 years (standard deviation, 10.7; range, 22-94). Almost half of the
population had a BMI of 30 or more (median, 29.7; IQR, 26.2-34.2).
The most common indication for surgery was osteoarthritis
(85%, n ¼ 3323). Spinal anesthesia was the most common anes-
thetic technique used (94%, n¼ 3666) for THA and TKA. Duration of
surgery as well as estimated blood loss was higher for THA than
TKA. There were 2024 primary unilateral TKA (87%), 89 primary
bilateral TKA (4%), 201 unilateral revision TKA (9%), and 2 uni-
compartmental TKA (<1%). There were 1444 primary unilateral
THA (90%), 7 primary bilateral THA (<1%), and 147 unilateral revi-
sion THA (9%).
Half of the patients received their ﬁrst dose of rivaroxaban
22 hours after surgery. The interval to ﬁrst dose ranged from 6 to
113 hours (median, 22; IQR, 20-24 hours). The ﬁrst dose of rivar-
oxaban was given signiﬁcantly sooner in patients who underwent
TKA (median, 22; IQR, 19-24 hours) when compared to those who
underwent THA (median, 24; IQR, 21-25 hours; P < .01).
Incidence and Timing of Symptomatic VTE
There were a total of 18 symptomatic proximal DVTs at post-
operative week 12 (0.46%; Table 2). Only 1 case of DVT wasidentiﬁed within 7 days of surgery. Only 2 symptomatic proximal
DVTs (0.05%) were identiﬁed while patients were receiving rivar-
oxaban. The median time to occurrence of DVT was POD 45 (IQR,
48-67). The majority of DVT events (89%, n ¼ 16) occurred after
rivaroxaban had been discontinued (Fig. 3). Three of 6 patients
(50%) with DVT after primary TKA had a history of VTE compared
with only 1 of 11 (9%) patients following primary THA. There was a
signiﬁcant association for the occurrence of DVT in patients with
previous history of VTE following primary TKA with an RR ¼ 2.39
(95% conﬁdence interval [CI], 0.82-6.99). There was no statistically
signiﬁcant association between DVT occurrence and a history of
VTE in primary THA (P ¼ .35).
There were a total of 28 symptomatic PEs at postoperative week
12 (0.7%). Thirteen PEs (46%) occurred within 7 days of surgery
(median POD, 10; IQR, 5-36). Age, sex, BMI, type of anesthesia, and
duration of surgery did not differ between those who had a
thromboembolic event and those who did not. There was a trend
between occurrence of PE and having had a major surgery within
previous 3 months in the primary THA (P ¼ .05). In the present
study, there were no statistically signiﬁcant associations between
PE and other risk factors in either TKA or THA.
The incidence of DVT at postoperative week 12 was signiﬁcantly
higher in THA compared to TKA (0.75%, n ¼ 12 vs 0.26%, n ¼ 6;
P < .03). However, the incidence of PE at postoperative week 12 did
not differ between THA and TKA patients (0.75%, n ¼ 12 vs 0.69%,
n ¼ 16; P ¼ .83; Table 2).
Bleeding, Transfusion Requirements, and Deaths
Thirty-six patients (0.9%) had clinically relevant bleeding events
during the study period: 6 major (0.15%) and 30 nonmajor (0.8%;
Table 2). Twenty-nine bleeding events (4 major and 25 nonmajor)
occurred while taking rivaroxaban (0.7%). The incidence of surgical
site bleeding while on prophylaxis was 0.5% (n¼ 20). Three surgical
site bleeding events were considered major: 1 leading to death in a
patient with previously undiagnosed VonWillebrand's disease and
2 leading to reoperation. Surgical site bleeding was equivalent
following THA compared with TKA (0.68% vs 0.39%; P ¼ .37). The
incidence of nonsurgical site bleeding while on prophylaxis was
0.28% (n ¼ 11); 2 of these bleeding events were characterized as
major. Upper gastrointestinal bleeding accounted for 64% of
all nonsurgical site bleeding events while on prophylaxis. Nonsur-
gical site bleeding while on prophylaxis did not vary across
procedure type.
4900 patients had TJA 
during study period
748 declined to 
participate in study 4152  patients consented
238 patients received 
anticoagulant other than 
rivaroxaban
3914 patients treated 
with rivaroxaban
74 patients not available 
for 3 month follow-up per 
protocol
62 patients had current 
results on hospital 
information systems 
indicating patient alive 
after 3 months
12 patients without 
current results on 
hospital system were not 
found in national 
obituary registry= likely 
alive
Fig. 2. Study participants and follow-up. TJA, total joint arthroplasty.
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fusion requirements were signiﬁcantly higher following THA
compared to TKA (7% vs 3%, P < .01; Table 2).
There were 9 deaths during the study period (0.2%). No deaths
were attributed to thromboembolic causes. Two deaths occurred
during the perioperative period. One cause of death was considered
tobeundeterminedafterundergoingautopsy. Therewasnoevidence
of DVT, PE, myocardial infarction, stroke, or bleeding. The second
deathwas characterized as diffuse fatal hemorrhage in the setting of
previously undiagnosed VonWillebrand's disease (Table 3).
Discussion
This phase IV, prospective, observational, noninterventional
study focused on clinically relevant outcome measures that aneffective thromboprophylaxis program needs to balance: preven-
tion of symptomatic VTE vs major bleeding events. It would not be
an acceptable trade-off for surgeons or their patients if the effective
thromboprophylactic drug resulted in excessive bleeding and
increased postoperative complications. This study demonstrates
that rivaroxaban appears to protect patients against symptomatic
PE and is not frequently associated with major bleeding events
when used in a real-world setting as described.
The overall symptomatic proximal DVT rate in 3914 patients
within 3 months of surgery was 0.5%. This compares with
proximal DVT rates following THA between 0.1% and 0.6% at 35
days postsurgery in RECORD 1 and 2 [1,2] and following TKA
between 0.3% and 1.1% at 15 days postsurgery in RECORD 3 and
4 measured the day after completion of treatment [3,4]. Using
the same time intervals as the RECORD trials, our DVT rate in
Table 1
Demographics of the Sample Including Type of Anesthetic, Duration of Surgery, and Estimated Blood Loss by Procedure.
Patient Characteristics and
Surgical Parameters
Total Knee Arthroplasty (N ¼ 2316) Total Hip Arthroplasty (N ¼ 1598)
Primary Unilateral
(n ¼ 2024)
Primary Bilateral
(n ¼ 89)
Revision
(n ¼ 201)
Unicom
(n ¼ 2)
Primary Unilateral
(n ¼ 1444)
Primary Bilateral
(n ¼ 7)
Revision
(n ¼ 147)
Gender
Male, n (%) 735 (36) 47 (52) 79 (39) 1 (50) 606 (42) 1 (14) 64 (44)
Female, n (%) 1289 (64) 42 (48) 122 (61) 1 (50) 838 (58) 6 (86) 83 (56)
Age
Average (SD) 66 (10) 62 (8) 67 (11) 48 (10) 65 (11) 55 (7) 65 (13)
Range 33-93 38-80 40-94 44-51 22-94 46-66 32-91
Median 65 61 66 47.5 66 52 65
Body mass index
Average (SD) 32 (7) 30 (5) 32 (6) 28 (0.23) 29 (6) 30 (7) 28 (5)
Range 17-67 19-45 18-54 28 16-57 18-39 17-51
Median 31 29 31 28 28 29 28
Previous VTE/DVT (n ¼ 175) 93 (5) 1 (1) 15 (7) 0 56 (4) 0 10 (7)
Present DVT, n (%) 3/90 (3) 0/1 0/15 1/53 (2) 0/10
Present PE, n (%) 1/90 (1) 0/1 0/15 0/53 0/10
Type of anesthesia
General, n (%) 136 (7) 4 (5) 24 (12) 0 93 (6) 3 (43) 37 (26)
Spinal, n (%) 1903 (94) 84 (94) 175 (89) 2 1376 (95) 5 (71) 117 (80)
Epidural, n (%) 9 (<1) 68 (77) 8 (4) 0 13 (<1) 4 (57) 25 (17)
Duration of surgery
Average (SD) 72 (22) 114 (31) 110 (42) 85 (6) 74 (18) 132 (16) 143 (67)
Median 71 108 104 85 73 135 132
Estimated blood loss
Average (SD) 124 (87) 155 (79) 195 (215) 100 (0) 374 (229) 579 (180) 927 (819)
Median 100 150 100 100 350 550 650
Pathology
OA, n (%) 1932 (95) 87 (98) 0 0 1298 (90) 6 (86) 0
Inﬂammatory, n (%) 45 (2) 2 (2) 0 0 32 (2) 0 0
Fracture, n (%) 0 0 0 0 10 (<1) 0 0
Unicom, unicompartmental; SD, standard deviation; VTE, venous thromboembolism; DVT, deep venous thrombosis; PE, pulmonary embolism; OA, osteoarthritis.
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for TKA at day 15 postsurgery was 0.04%. The DVT rate in TKA
was signiﬁcantly lower than the reported rates from RECORD
3 and 4 because we were not investigating asymptomatic
patients.
Treating all 1444 primary THA patients for 35 days with
rivaroxaban may have theoretically prevented 1-3 symptomatic
proximal DVT, as 1 occurred on POD 34 and 2 more on POD
36. Nine DVT occurred after POD 35, representing 82% of DVT
following THA. None of these patients had a history of VTE.Table 2
Thromboembolic Events, Deaths, Bleeding, and Transfusions by Surgical Procedure.
Clinical Event
and Outcome
Total Knee Arthroplasty (N ¼ 2316)
Primary Unilateral
(n ¼ 2024)
Primary Bilateral
(n ¼ 89)
Revisio
(n ¼ 20
Deep venous thrombosis, n ¼ 18
Perioperative (POD 7) 1 0 0
6 wk (POD 8-42) 2 0 0
3 mo (POD 43-90) 3 0 0
Total 6 (0.3%) 0 0
Pulmonary embolism, n ¼ 28
Perioperative (POD 7) 10 0 1
6 wk (POD 8-42) 2 1 0
3 mo (POD 43-90) 2 0 0
Total 14 (0.7%) 1 (1.1%) 1 (0.5%
Death, n ¼ 9 3 (0.1%) 0 0
Surgical bleeding, n ¼ 22
Major, n ¼ 3 2 0 0
Nonmajor, n ¼ 19 5 1 1
Nonsurgical bleeding, n ¼ 14
Major, n ¼ 3 1 0 0
Nonmajor, n ¼ 11 6 0 0
Transfusion, n ¼ 160 42 (2%) 15 (17%) 10 (5%
Unicom, unicompartmental; POD, postoperative day.The RECORD 1 and 2 studies reported nonfatal PE rates of 0.1%-
0.3% for THA at 35 days postsurgery [1,2] having received 35 days of
treatment on rivaroxaban. Our PE rate in THA at 35 days post-
surgery was 0.4% having received 15 days of treatment on rivar-
oxaban. The RECORD 3 and 4 studies reported nonfatal PE rates of
0%-0.4% following TKA at 15 days [3,4]. Our PE rate for all TKA at day
15 postsurgery was 0.5%. The PE rates for THA and TKA are close to
the rates reported in the RECORD trials. The overall PE rate (0.7%)
reported in this study is affected by the following: (1) a relatively
high incidence of symptomatic PE following TKA within 7 days ofTotal Hip Arthroplasty (N ¼ 1598)
n
1)
Unicom
(n ¼ 2)
Primary Unilateral
(n ¼ 1444)
Primary Bilateral
(n ¼ 7)
Revision
(n ¼ 147)
0 0 0 0
0 4 0 1
0 7 0 0
0 11 (0.8%) 0 1 (0.7%)
0 1 0 1
0 4 0 1
0 5 0 0
) 0 10 (0.7%) 0 2 (1.3%)
0 6 (0.4%) 0 0
0 0 0 1
0 9 1 2
0 1 0 1
0 5 0 0
) 0 54 (3%) 2 (27%) 37 (26%)
Fig. 3. Cumulative incidence plots of thromboembolic events by joint replaced (hip and knee).
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occurrence of PE following THA and TKA between 35 days and 90
days.
The frequent occurrence of PE following TKA within 7 days of
surgery was striking but not unique. Kerr and Linkins [5] reported a
perioperative PE rate of 4.6% following TKA and 0.4% following THA
in a retrospective review of 683 primary and revision THA and TKA
using low-molecular-weight heparin. Clayton et al [6] reported 73%
of PE events in their study following TKA occurred on or before day
5 following surgery. In our study, nearly 50% of the PE events
occurred within 7 days of surgery and 11 of 13 (85%) of these PE
followed TKA. The diagnosis of PE was only made with central or
segmental ﬁlling defects. Several authors have questioned whether
there is really an increase in PE or has there been an increase in our
ability to image the pulmonary circulation with relatively nonin-
vasive tests [6-8].
A previous meta-analysis has suggested a history of VTE has a
strong association with postoperative VTE following THA and TKA
with odds ratio of 10.7 (CI, 2.4-47.5; P ¼ .002) [9]. The relative risk
for development of DVT in primary TKA in this study was 2.39
(CI, 0.82-6.99) in patients with a history of VTE. The relative risk for
development of DVT following primary THA was not increased.
None of the late-occurring DVT between week 6 and 12 had a
history of VTE. The relative risk for development of PE following
THA and TKA was not increased.
The interval between the completion of surgery and the ﬁrst
dose of rivaroxaban was statistically longer for THA (median, 24;Table 3
Deaths During Study by Procedure and Adjudicated Cause.
Patient Type of Surgery Postoperative Day Age Sex BMI A
1 THA 2 46 M 31 Y
2 TKA 4 70 M 38 Y
3 THA 14 61 F 31 N
4 TKA 18 65 M 35 N
5 THA 38 84 F 18 N
6 THA 45 59 M 29 N
7 TKA 45 67 F 36 N
8 THA 61 74 M 26 N
9 THA 63 75 M 40 N
BMI, body mass index; THA, total hip arthroplasty; TKA, total knee arthroplasty; M, malIQR, 21-25 hours) vs TKA (median, 22; IQR, 19-24 hours; P < .01).
This difference is likely due to local operating room scheduling
where a THA ismost commonly booked as the ﬁrst case. Therewere
2 PE (0.1%) events following THA and 10 PE (0.4%) following TKA
within 7 days of surgery. The longer interval to ﬁrst dose did not
appear to give rise to more frequent events following THA. It is not
clear from these data whether TKA is at a higher risk for PE despite
having a shorter interval to ﬁrst dose of rivaroxaban.
There were 4 major bleeding events while on rivaroxaban,
including 48 hours after the last dose (0.1%). There were 2 major
surgical site bleeds following THA (0.1%) and 2 following TKA (0.1%).
This compares with the rates of major bleeding reported in the
RECORD trials following THA of 0.1%-0.3% [1,2] and following TKA of
0.7% [3,4]. The combination of major and nonmajor bleeding
following THAwas 1.1% compared with 3.2%-3.3% in RECORD 1 and
2. The combination of major and clinically relevant nonmajor
bleeding following TKA was 0.6% compared with 3%-3.2% in
RECORD 3 and 4. The incidence of major bleeding was less than
previously reported in the randomized controlled trials. This may
be due to the ﬁrst dose of rivaroxaban being given the morning
after surgery and treatment lasting a total of 15 days for both THA
and TKA.
The overall transfusion rate in this study was 4.7%. The trans-
fusion rate following primary unilateral THA was 7%. The trans-
fusion rate following THA in the RECORD studies was 40%-55% [1,2].
The transfusion rate following TKA was 3%. The transfusion rate
following TKA in the RECORD studies was 41%-51% [3,4]. The largeutopsy Adjudicated Cause
es Undetermined. No PE, myocardial infarction, bleed, or stroke
es Fatal hemorrhage, previously undiagnosed Von Willebrand's disease
o Drug toxicity
o Cardiac failure
o Pneumonia
o Cardiac death
o Cardiac death
o Cardiac death
o Metastatic cancer
e; F, female; PE, pulmonary embolism.
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fusion criteria and surgical practice. Therewas no routine use of cell
saver, reinfusion drains, tranexamic acid, or drains in our cases.
Tourniquets were routinely used for TKA and about half of the
surgeons deﬂated the tourniquet before wound closure.
The overall death rate was 0.3%. None of these deaths were
attributed to thromboembolic events. The RECORD trials reported
death rates following THA of 0.2%-0.3% and following TKA of
0%-0.4%. These death rates are not unexpected given the extent of
the surgery, the age of the patients, and the medical comorbidities
in this surgical population.
Limitations
This study had a number of limitations. This is a phase IV,
observational study without a comparison group. We can only
comment on the outcome measures relative to previously reported
randomized controlled trials. Despite following up with 99.7% of
3914 patients, the event rates for DVT, PE, death, and bleeding were
very low (<1%) and not suitable for rigorous additional regression
analyses.
Conclusions
This prospective, observational, phase IV study of rivaroxaban at
3-month follow-up capturing 99.7% of patients has shown the
following: a symptomatic proximal DVT rate of 0.5%; symptomatic
PE rate of 0.7%; major bleeding rate of 0.1% while on prophylaxis;
death rate of 0.3%; and an overall transfusion rate of 4.7% following
primary and revision THA and TKA. History of VTE was only asso-
ciated with symptomatic proximal DVT following primary TKA in
this study. The occurrence of VTE 5-12 weeks following THA may
warrant some form of thromboprophylaxis for a longer duration.
Our data suggest that rivaroxaban appears to protect a real-world
cohort of unselected prospective patients from symptomatic VTEand not cause excessive major bleeding events following primary
and revision THA and TKA when used as described.Acknowledgments
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